PrognomIQ
PrognomiQ Is Enabling Early Disease Detection And Treatment
San Mateo, United States · Founded 2020 · $135.0M raised
- Headquarters
- San Mateo, California
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- prognomiq.com
- Total Funding
- $135.0M
- Last Round
- $34.0M Series CNov 2024
- Rounds
- 3
About
PrognomiQ is a diagnostics company developing multi-omic blood tests for early detection and treatment of cancer and other complex diseases. By combining proprietary proteomics data at unprecedented scale with genomic and metabolomic data, the company builds transformative liquid biopsy products, including Provue Lung for early-stage lung cancer identification.
Summary
PrognomIQ is a Biotech company based in San Mateo, United States, founded in 2020. It has raised $135.0M in total across 3 rounds, most recently a $34.0M Series C round in Nov 2024. Investors include Seer Inc, Wing VC and Maverick Ventures.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...